Commonwealth Medicine; Center for Health Policy and Research; Clinical Pharmacy Services; Office of Clinical Affairs/MassHealth
Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Health Services Administration | Health Services Research | Pharmaceutical Preparations | Pharmacy and Pharmaceutical Sciences | Respiratory Tract Diseases | Therapeutics
This poster gives an overview of pulmonary exacerbation rates pre- and post-initiation of Lumacaftor/Ivacaftor (LUM/IVA) in Massachusetts' Medicaid program. Pulmonary disease is one of the leading causes of morbidity and mortality among patients with cystic fibrosis. LUM/IVA has been effective in improving pulmonary outcomes in two observational studies, but before this study, there had been no published data evaluating real-world outcomes for Medicaid patients receiving this therapy.
This poster on the impact of a drug for patients with cystic fibrosis was shared during the 2018 Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting and awarded a gold ribbon. The poster abstracts were evaluated on relevance, originality, quality, bias and clarity. Only 20 percent of submitted abstracts were honored with awards.
Medicaid, Pharmacy, Drug Utilization Review
Rights and Permissions
© 2018 University of Massachusetts Medical School
2018 Academy of Managed Care Pharmacy Managed Care and Specialty Pharmacy Annual Meeting
Tesell, Mark A.; Stevens, Karen; Greenwood, Bonnie C.; Alper, Caroline J.; Lenz, Kimberly J.; and Jeffrey, Paul L., "Impact of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population" (2018). Commonwealth Medicine Publications. 190.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Health Services Administration Commons, Health Services Research Commons, Pharmaceutical Preparations Commons, Pharmacy and Pharmaceutical Sciences Commons, Respiratory Tract Diseases Commons, Therapeutics Commons